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Abstract
Increasing evidence points to defects in autophagy as a common denominator in most
neurodegenerative conditions. Progressive functional decline in the autophagy-lysosomal
pathway (ALP) occurs with age, and the consequent impairment in protein processing
capacity has been associated with a higher risk of neurodegeneration. Defects in cathepsin
D (CD) processing and α-synuclein degradation causing its accumulation in lysosomes are
particularly relevant for the development of Parkinson's disease (PD). However, the mecha-
nism by which alterations in CD maturation and α-synuclein degradation leads to autophagy
defects in PD neurons is still uncertain. Here we demonstrate that MPR300 shuttling
between endosomes and the trans Golgi network is altered in α-synuclein overexpressing
neurons. Consequently, CD is not correctly trafficked to lysosomes and cannot be pro-
cessed to generate its mature active form, leading to a reduced CD-mediated α-synuclein
degradation and α-synuclein accumulation in neurons. MPR300 is downregulated in brain
from α-synuclein overexpressing animal models and in PD patients with early diagnosis.
These data indicate MPR300 as crucial player in the autophagy-lysosomal dysfunctions
reported in PD and pinpoint MRP300 as a potential biomarker for PD.
Introduction
Emerging evidence points to an imbalance between synthesis and degradation of proteins as a
leading cause for the aggregation of redundant proteins into insoluble deposits that impair the
functions of neurons and contribute to the onset and progression of neurodegenerative disease,
such as Parkinson's (PD) and Alzheimer’s disease [1, 2]. PD is the most common neurodegen-
erative movement disorder characterized by the severe degeneration of neurons in the
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substantia nigra pars compacta and progressive changes in other brain regions [3–5]. At the
cellular level, neuronal loss is preceded by synapse degeneration and the presence of cyto-
plasmic inclusions known as Lewy bodies, largely consisting of fibrils formed from insoluble α-
synuclein (α-syn) protein [4, 6, 7].
α-Syn is a synaptic protein mainly localized in the proximity of synaptic vesicles [8, 9]. The
various physiological roles of α-syn are still under investigation, however it is known to bind
lipid membranes on synaptic vesicles, mitochondria and the Golgi apparatus [10]. Accordingly,
α-syn serves as a molecular chaperone, facilitating SNARE complex assembly at the synapse
[11, 12]. Furthermore, it controls the dynamics of neurotransmitter release and clathrin-depen-
dent replacement of the pool of synaptic vesicles [13], as well as participating in the stabiliza-
tion of mitochondrial membrane proteins [14]. The intracellular homeostasis of α-syn requires
the proper degradation of the protein by three mechanisms: chaperone-mediated autophagy,
macroautophagy and the ubiquitin-proteasome system. Impairment of these pathways is
hypothesized to be an important pathogenic factor in sporadic forms of PD [15, 16] whose rela-
tive contributions can be subjected to several regulatory mechanisms, e.g. by aging [17]. The
impaired cell trafficking in the autophagy-lysosomal pathway (ALP) results in the exosomal
release of α-syn [1] and likely of other target proteins.
Cathepsin D (CD) is a lysosomal protease previously demonstrated to cleave α-syn and
decrease its toxicity in cell lines [18]. Additionally, overexpression of CD reduces α-syn aggre-
gation in cell models and CD deficiency increases the neuronal aggregation of α-syn [19, 20].
CD is synthesized as an inactive pro-form (proCD) in the endoplasmatic reticulum. Upon final
maturation of proCD in the trans Golgi-network (TGN) and the glycosylation with mannose
6-phosphate, the protein is translocated to endosomal compartments. The transport of CD
from the TGN to endosomes is mediated by the cation-independent mannose-6-phosphate
receptor, a type-1 receptor also known as the 300 kDa mannose-6-phosphate receptor
(MPR300). In the endosomes, proCD is released from the receptor and retained in the com-
partment during its maturation and endosomal trafficking into lysosomes. MPR300 recycles
back to the TGN to initiate a new cycle [21].
Here we investigated whether alterations or defects in proteins involved in α-syn trafficking
might be involved in PD and thus be exploitable as prognostic indicators. We found CD levels
are significantly reduced in brain tissue from transgenic (homozygote and heterozygote) α-
syn-overexpressing mice models of PD. The reduction in CD results from defective trafficking
and sorting. This trafficking deficit is related to a decrease in MPR300 levels in neurons, with a
large amount of MPR300 being processed into lysosomes and/or released into the media of α-
syn overexpressing cells and neurons, or found in the soluble protein brain tissue fraction of α-
syn overexpressing mice. Furthermore, MPR300 levels were also decreased in human brain tis-
sues from patients in the early stages of PD compared to aged matched healthy controls. All
together these results point to a new unsuspected player in controlling α-syn degradation in
neurons. MPR300 reduces proCD transport to late endosomes and thereby the quantities of
mature CD in lysosomes. The resultant defect in CD activity blocks α-syn degradation leading
to its intracellular accumulation and to lysosomal dysfunction. The crucial increased release of
MPR300 and its concomitant decrease in intracellular levels, also supported by data from PD
patients, point to MPR300 as a valuable potential tool in PD.
Materials and Methods
Human tissue samples and tissue processing
Human tissue samples from the anterior cingulate cortex of autopsy-confirmed sporadic PD
subjects (n = 6, 4 men and 2 women, age 76±2) and matched clinical and neuropathological
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controls (n = 9, 5 men and 4 women, age 74±3) were provided by the Sydney Brain Bank fol-
lowing appropriate institutional approvals. In order to assess early PD, cases were restricted to
α-syn pathology at Braak stage 4. At this stage the anterior cingulate cortex has increased SDS-
soluble α-syn, but does not yet have Lewy body pathology [22]. All PD cases met the UK Brain
Bank clinical criteria for a diagnosis of PD and had no other neurodegenerative conditions.
The cases analysed have been previously used to assess lipids, and α-syn levels in early PD [22].
As previously described [22], Tris-buffered saline (TBS) and SDS-soluble proteins were seri-
ally extracted from 250 mg of fresh-frozen brain tissue from each case. Briefly, tissue was
mechanically homogenized in 10 volumes TBS homogenization buffer (50 mM Tris, 125 mM
NaCl, pH 7.4, 5 mM EDTA, 0.02% sodium azide) containing protease inhibitor cocktail
(Roche), followed by centrifugation at 120,000 x g for 2 h at 4°C, with the supernatant collected
as the TBS-soluble fraction containing cytosolic proteins. The pellet was resuspended in SDS
solubilization buffer (TBS homogenization buffer containing 5% SDS), sonicated (2 x 10 s
bursts) and centrifuged at 100,000 x g for 30 min at 25°C, with the supernatant collected as the
SDS-soluble fraction containing membrane-associated proteins. Protein concentrations were
measured using a bicinchoninic acid assay (Pierce BCA Protein Assay Kit, Thermo Scientific),
following the manufacturer’s instructions with samples then stored at -80°C until use.
Animal strains
The animals used for these studies were backcrossed to C57Bl/6J mice. The mice were bred and
group housed in the Lab Animal Centre of Taconic (Aarhus, DK) at an ambient temperature
of 22–23°C and on a 12/12 h dark/light cycle (lights on 7 a.m.). A total of fourteen 3-month,
four 6-month and four 12-month old WT and ASOTg/Tg male, 3, 6 and 12-month-old ASOTg/+
and four 3-month old WT and 6 ASOTg/Tg male mice were used for experiments. Primary cul-
tures were obtained from 6WT and 6 ASOTg/Tg pregnant mice. Prior to euthanasia, all of the
mice were anesthetized by 2-bromo-2-chloro-1,1,1-trifluoroethane inhalation and euthanized
in accordance with international guidelines on the ethical use of animals (European Communi-
ties Council Directive of November 24, 1986; 86/609/EEC) and Danish guidelines. Heterozy-
gous transgenic mice with mixed C57BL/6-DBA/2 background and expressing human α-syn
under the Thy-1 promotor were a kind gift from Dr. Eliezer Masliah and have previously been
described in detail [23]. Homozygous α-syn mice (backcrossed in C57BI6 for at least 9 genera-
tions), overexpressing wild-type human α-syn under the control of the partial mouse α-syn
promoter, were provided by Dr P.H. Kallunki from A.S. Lundbeck and have previously been
described in detail [24, 25].
Cell cultures and neuronal primary cultures
SH-SY5Y cells were transfected using Fugene6 Transfection Reagent (Promega) with an α-syn
construct in pCDNA3.1(-)(Zeo) (Invitrogene). 48 h after transfection, cells were transferred to
96 wells plates in culture medium supplemented with Zeocine. Stable clones were tested for α-
syn expression using western blot (WB) and a single clone with homogeneous α-syn staining
selected from the positive clones (from hereon referred to as ASO cells).
Cortical neurons were prepared from embryonic day 17/18 (E17/E18) mice, as previously
reported [26]. Neurons were dissected in HBSS buffered with HEPES and dissociated via
papain treatment. A total of 200,000 cells were plated on slides pre-coated with poly-l-lysine.
After 2 d of culturing in neurobasal medium with B-27 supplement and glutamax, cytosine ara-
binofuranoside was added to reduce glial proliferation. ASO hippocampal neurons appeared
very difficult to keep in culture when compared to the correspondent background matched
WT, starting to dye after 10 days of culturing and showing an intense glial cell proliferation. To
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avoid these difficulties, immunofluorescence and WB analysis were performed on 10 day
plated hippocampal neurons.
NH4Cl and chloroquine were obtained from Sigma Chemical (DK). 5M NH4Cl and 50mM
chloroquine stock solutions were made in sterile distilled water. Each drug was used at the low-
est concentration needed to have an effect (NH4Cl 5mM; Chloroquine 10μM), and neurons
were treated for the minimum amount of time required to see an effect on MPR300 vesicle
number (6 h) to minimize secondary effects of any of these drugs [27]. Cell viability was
assessed before and after drug exposure both in CTRL and ASO cells.
Western blotting
Equal amounts (30 μg) of soluble animal and cellular proteins and SDS-soluble human tissue
proteins were separated on 4–12% Bis-Tris SDS-PAGE gels (Invitrogen, DK or Novex system,
Life Technologies), blotted onto nitrocellulose membranes (Amersham, DK or Biorad), and
incubated overnight with the appropriate primary antibody (see below). Visualisation of pro-
tein bands was performed on a Chemidoc MP imaging system (Biorad) and Image Lab soft-
ware (Biorad) used to quantify relative protein intensity with β-actin used to normalise for
protein loading.
Media from control and ASO cells were processed following the procedure previously
described by Matrone et al. [28]. Shortly 1.500.000 control and ASO cells were plated in 2ml of
media. After 24hrs media was collected and ultra-centrifuged at 100000rpm for 12hrs. Cells
were processed for WB analysis. Pellets obtained after ultracentrifugation were suspended in
100ul of loading buffer containing SDS 2% and 1/10 of their total volumes were loaded on the
gel for WB analysis. Hsc70 protein was used as protein loading control for quantification of rel-
ative protein intensity [29].
The antibodies for WB and immunofluorescence were as follow: rabbit-anti-α-syn (ASY1)
[30, 31], mouse-anti-EEA1 (Abcam), mouse-anti-α-syn (BD biosciences), rabbit-anti-human
MPR300 (2C2) [32], goat-anti-MPR300 (clone k21, Santa Cruz Biotech), anti-MPR300
(Abcam), goat-anti-Cathepsin D (Santa Cruz Biotech), sheep-anti-TGN46 (AbD Serotec), rab-
bit-anti-Lamp1 (clone ab24170, Abcam), rabbit-anti-Rab4 (BD Transduction), rabbit-anti-
Rab7 (Abcam), rabbit-anti-GFP (Sigma), rabbit-anti- β -actin (Sigma), rabbit anti-β-actin
(Abcam) and Alexa-fluor labelled secondary antibodies (Invitrogen).
Animal brain tissue and cellular fractionations
Whole mouse brains were sonicated in a lysis buffer containing 20 mM Tris-base pH 7.4, 250
mM sucrose, 1 mM EDTA, 1 mM EGTA plus protease (Roche, Complete) and phosphatase
inhibitors. For soluble vs. insoluble fractionations, 250μg hippocampal tissues from each strain
were homogenized in 300μl of lysis buffer and the lysates were firstly spun at 1,000 g for 15
min and then for an additional 4 h at 100,000 g. The soluble fraction was separated from the
pellet and analysed by WB loading 1/10 of the total volume (30μl). Pellets were suspended in
100μl of loading buffer containing β-mercaptoethanol and 10μl of each sample was loaded and
analysed by WB.
Vesicular pH assay
Lysosomal pH was determined in SH-SY5Y cells and stably transfected α-syn SH-SY5Y cells
(ASO cells) as previously described [33]. Cells were incubated in the presence of 10 μg/mL
nanoparticle for 24 h at 37°C in normal growth medium. The cells were then washed three
times with ice-cold heparin (20 units/mL in PBS), once with PBS and kept in growth medium
without phenol red for observation by confocal microscopy. Cells were either imaged
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immediately or treated with 100 nM Bafolimycin A1 for 45 min before imaging. Images were
captured with a Leica TCS SP5 confocal microscope with a 63x water/immersion objective
(Leica Microsystems, Germany). The microscope was equipped with an incubator box and
CO2 supply for optimal growth conditions during imaging (Life Imaging Services, Switzer-
land). Images were acquired with fixed settings for all samples and the corresponding calibra-
tion curve. Two-color images were obtained by sequential line scanning with the following
excitation/ emission wavelengths: 488/493-560 nm and 561/566-680 nm. The calibration curve
was prepared by diluting the nanosensor in buffers (20 mM phosphate/20 mM citrate/20 mM
malate/100 mMNaCl) from pH 2.8–7.5 with a final nanosensor concentration of 8 mg/mL.
2.5 μL of each calibration solution was transferred to a diagnostic microscopy slide, sealed with
a cover glass and imaged. Image analysis was performed as described previously with a pixel
based method [34]. Briefly, image processing was used in order to determine which pixels are
actual signal from nanosensors and the included pixels were then converted to pH via the cali-
bration curve. pH histograms are presented as mean ± SEM. 800–1000 data points were ana-
lysed for each cell line.
Confocal microscopy and high content screening analysis
Cells and neurons were fixed for 20 min in PBS containing 4% formaldehyde, permeabilized
with 0.25% Saponin (5–10 min, 20°C), and processed for single labelling with the appropriate
antibody. Secondary antibodies coupled to Alexa dyes (488 or 594) were from Invitrogen.
Nuclei were visualized by staining with Hoechst dye 33258 (1 μg/ml) (Sigma). Digital images
were obtained with a Zeiss LSM confocal lsm780 system using 63× oil NA 1.3 objective. Quan-
tification of the co-localization experiments was performed using Zen 2009 software. Pearson
coefficients (R coefficients) were used as co-localization coefficients, following the same proce-
dure previously described by La Rosa et al., 2015 [35]
Olympus automated Scan^R imaging High Content imaging station base on Olympus
BX73 microscope, were used for quantitative analysis [36, 37]. Images were acquired with a 40
times objective, single band emission filters for Hoechst 33258, Alexa-Fluor-488 and Alexa-
Fluor-568, and a Hamamatsu EMMCD camera. Acquired single-layer images were back-
ground-subtracted before image analysis, after which an edge-detection algorithm was used for
segmentation of nuclei and stained vesicles. This algorithm use gradient intensities in the
image to identify vesicles. If a closed connecting line (edge) can be drawn around an object, the
object is segmented, and the selection is independent of the vesicle shapes. However, vesicles
larger than 3 μm in diameter were not marked. Images with artifacts or zero cells were gated
out, where after the number of vesicles per cell was determined by calculating for each image
the ratio of vesicles to nuclei. The number, area, and morphology of vesicles from at least 104
cells for each experiment (5 experiments in triplicate) were detected and analysed.
Real-time PCR for mRNA quantification
Total RNA was isolated from cortex of transgenic mice overexpressing α-syn (n = 6) and non-
transgenic littermates (n = 4) using NucleoSpin RNA kit (Macerey-Nagel). The cDNA was syn-
thesized from 0.5 μg total RNA in 20 μl total reaction volume using an iScript cDNA synthesis
kit (Biorad). The primer sequence is shown below. Real-time PCR was performed with a Light-
cycler 480 SYBR Green I master mix on a LightCycle480 instrument (Roche). Primers for the
two mouse normalizer genes (Ywhaz and Gapdh) were purchased from PrimerDesign Ltd
(Rownhams, UK). Intron spanning primer pairs for Igf2r and Ctsd, were designed using
Primer3 [38]. Standard curves were performed for all genes to ensure efficiency above 90%.
Minus RT and blank water controls were included. Normalization was performed using the
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average of Ywhaz and Gapdh. Fold change for all samples was calculated by comparing to the
average of the four Wt mice. To compare the RNA levels between the two groups (transgenic
mice overexpressing α-syn andWTmice), all fold changes were log transformed to ensure nor-
mal distribution and a two-sided unpaired t-test performed.
Statistical analysis
Data were expressed as means ± SEM. The various statistical tests used are indicated in the fig-
ure legends. We performed statistical analysis using GraphPad Prism (version 5.0c, USA). In
experiments involving two experimental groups and a single, non-repeated, dependent vari-
able, data were analysed using Student's t-test. When experiments involved three groups of ani-
mals or repeated measurements, the means were compared using, as required, either one- or
two-way analysis of variance (ANOVA). Post hoc comparisons were made using Tukey's test,
when appropriate.
Multivariate analysis using SPSS (IBM, Chicago, IL), covarying for age and post-mortem
delay, was used to determine significant differences (set at p< 0.05) in MPR300 or α-syn pro-
tein levels in human brain tissue.
Results and Discussion
α-Synuclein downregulates Cathepsin D
A large body of data points to CD as a modulator of α-syn degradation in lysosomes [18–20,
39, 40], however the interplay between CD and α-syn pathway in PD is still unclear. In order
to analyse how α-syn overexpression compromises lysosomal and CD activity, we firstly per-
formed confocal microscopy analysis for CD in a α-syn overexpressing SH-SY5Y cell line
(ASO cells) (Fig 1A) and assessed the number of CD positive vesicles pr. nuclei relative to con-
trols (Ctrl) (Fig 1D). We found that the number of CD-positive vesicles from ASO cells was
around half that of controls, while the area of the vesicles did not change (Fig 1D). Alterations
in the CD pathway can be indicative of a lysosomal deficit [41]. Consistent with this, confocal
microscopy analysis indicated the presence of dense Lamp1-positive areas in ASO cells, sug-
gesting that lysosome vesicles were likely fused to form bigger condensed areas (Fig 1C). Nota-
bly, while the area of Lamp1-positive vesicles was increased, the number of Lamp1-positive
vesicles was not significantly changed (Fig 1D), which is a typical phenotype for cells with
reduced lysosomal activity [41]. Consistently, WB analysis did not show significant differences
in the Lamp1 expression levels between Ctrl and ASO cell line (Fig 1E). Additionally, WB anal-
ysis revealed a reduction in the mature form of CD (32 kDa and 14 kDa) and an increase in
proCD levels in ASO cells (Fig 1E). Alteration in the pH in vesicles is considered to play an
important role in aging and neuronal degeneration [42] and the vesicular pH in lysosomes is
responsible for the maturation of proCD to active CD [43]. It has been previously demon-
strated that the A53T α-syn mutation affects lysosomal acidification in PC12 cells, which leads
to lysosomal dysfunction [44]. In order to evaluate whether the reduction in CD cleavage was
due to alteration in the pH in the lumen of the lysosomes, Ctrl and ASO cells were incubated
for 24 h with triple-labelled pH sensitive nanosensor [45]. As shown in Fig 1F, vesicular pH in
the lysosomal vesicles from ASO cells (blue curve) was not significantly different to that of Ctrl
cells (SH-SY5Y, red curve) demonstrating that the defect in proCD conversion to CD was not
ascribable to alterations in lysosomal pH. As a positive control for these experiments, ASO and
Ctrl cells were incubated with 100 nM Bafilomycin A1 (purple curve and green curve, respec-
tively). Bafilomycin increases vesicular pH by blocking the vacuolar-type H+-ATPase, but does
not interfere with nanosensor [33, 34]. As indicated by the purple and green curves, both ASO
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Fig 1. CD and MPR are reduced in α-syn expressing SH-SY5Y cells. (A, B, C) Confocal microscopy analysis of single immunostaining for CD, MPR300
and Lamp1, respectively, in Ctrl and α-syn expressing SH-SY5Y cells (ASO). Scale bar 8 μm. Panels are representative of 3 different experiments. Images
were also acquired on an automated Olympus microscope and the number and the area (D) of the vesicles pr. nuclei quantified using Scan^R imaging
software (Olympus) (three slides per condition). (N = 5; Two tailed T-test) *P<0.05 vs Ctrl. The total number of vesicles was normalized to DAPI positive cells
and expressed as media of vesicles per cell. (E) WB analysis for proCD and CD cleaved peptides migrating at 32kDa and 14kDa, MPR300, Lamp1 and α-
syn from total lysate (30μg) of human stable-transfected α-syn overexpressing cells (ASO) and their correspondent empty-vector control (Ctrl) cells. A
representative picture showing the levels of α-syn in each sample is shown below. The optical density analysis is reported below. Data were normalized on
the basis of the correspondent β-actin values and expressed as % of Ctrl. The experiments were run 3 times in triplicate. (N = 3; Two tailed-T Test). (*)
p<0.05 and (**) p<0.01 vs Ctrl. (F) Ctrl and stable-transfected α-syn SH-SY5Y cells were treated with triple-labelled pH-sensitive nanosensors for 24 h and
imaged by confocal microscopy. The ratio of the intensity signals from the pH-sensitive and reference fluorophores was converted to pH via the calibration
curve. To ensure the assay was working, an increase in vesicular pH was induced in Ctrl and ASO cells by treatment with 100 nM Bafilomycin A1 that blocks
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and Ctrl pH values increased under Bafilomycin exposure, denoting that the experiments were
running correctly.
MPR300 expression is reduced in α-syn overexpressing (ASO) cell lines
and in ASOmice
Since the decreased CD processing in ASO cells was not due to alteration of vesicular pH, and
since the processing of CD is largely related to its MPR300-mediated trafficking towards endo-
somes and lysosomes [32], we hypothesized that MPR300 expression, trafficking and sorting
might be affected in our experimental conditions. First we assessed MPR300 levels in ASO and
Ctrl cells by IF and WB (Fig 1B and 1E) and found that MPR300 expression levels were indeed
decreased in ASO cells. In addition, as for CD, we noted a clear decrease in the number of
MPR300-positive vesicles in ASO cells (Fig 1D) that was consistent with the detected decrease
in protein expression levels. Interestingly, a correlation between an increased area and density
of lysosomes and reduced MPR300-mediated transport of CD and other acidic hydrolases has
previously been described under different experimental conditions [32, 46].
To further analyse the mechanism by which α-syn overexpression affects MPR300 expres-
sion we employed two different strains of α-syn-overexpressing mice (heterozygote, ASOTg/+,
and homozygote, ASOTg/Tg) [23–25]. We isolated cortex from 3, 6 and 12 month-old mice and
assessed α-syn protein levels by WB (Fig 2A). We noted that in both ASOTg/+ and ASOTg/Tg
mice a significant increase in α-syn levels was already detectable at 3-months, and this level
increased further with age (Fig 2A). Notably, we did not detect any obvious difference in α-syn
levels between the WT control samples with different background (Fig 2A, chart). Since we
were interested in the early events occurring in ASOTg/+ and ASOTg/Tg mice, we decided to
focus all our studies on 3-month-old mice. Consistent with our findings in ASO cell lines,
MPR300 levels and the mature CD, migrating at 32 kDa, were significantly reduced, while
proCD was higher in both ASOTg/+ and ASOTg/Tg cortical tissues (Fig 2B and 2C). In contrast,
the mature 14 kDa band of CD was only weakly visible in WT samples and almost completely
undetectable in ASOTg/+ and ASOTg/Tg tissues (data not shown). Notably, the mRNA levels of
both CD and MPR300 were not different between WT and ASO mice (Table 1). Overall these
data support our hypothesis that defects in MPR300 receptor likely play a role in the reduction
of active CD in lysosomes and consequently in the lysosomal deficiencies observed in ASO
cells.
A rearrangement in MPR300 trafficking affects CD cleavage in ASO
mice
To dissect the mechanism leading to the reduction of MPR300 in ASOTg/Tg tissues, we firstly
questioned whether MPR300 trafficking was altered. Since MPR300 is shuttled between the
TGN and endosome and only a small amount reaches the lysosome under normal conditions
[47, 48], we analysed its localization in the early (EEA1), trans Golgi network (TGN) and
late endosome (Rab7) (Fig 3A–3C). We hypothesized that the reduction of MPR300 from
ASOTg/Tg neurons might be due to its inefficient retrograde transport from the endosomes to
TGN. Such a defect would likely be followed by an augmented MPR300 transport to the late
endosome with its consequent degradation in the lysosome or secretion. Therefore, we assessed
the vacuolar-type H+-ATPase. Mean ± SEM (number of slides n = 10) are presented. A maximum of 7% and 0.5% of measurements fell outside the range of
the nanosensor for the bafilomycin A1-treated and untreated samples, respectively. Each experiment was repeated three times with similar results and for
each experiment between 800 and 1000 data points were acquired for every cell line.
doi:10.1371/journal.pone.0160501.g001
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Fig 2. CD andMPR300 protein levels are reduced in α-syn overexpressing mice cortex. (A) WB analysis for α-syn performed in total lysate from
cerebral cortical tissues of 3, 6 and 12 month-agedWT, ASOTg/+ and ASOTgTtg mice. WT tissues are from C57BL/6J mice (background matched to
ASOTg/Tg). No obvious differences in α-syn expression were detected between the twoWTmice with different background. N = 5; One-way Anova with
post-hoc Tukey test. (B, C) WB for MPR300 and proCD/CD in total lysate from cortex of heterozygous α-syn ASOTg/+ and homozygous α-syn ASOTg/Tg
mice respectively and their correspondent background matched controls. Charts of the band optical density (OD) are shown below each panel. Data were
normalized to the corresponding β-actin values and expressed as % of WT. (*) p<0.05 vsWT. The experiments were run 5 times in triplicate. N = 5. Two
tailed T-Test.
doi:10.1371/journal.pone.0160501.g002
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whether MPR300 was increased in late endosomes (Rab7-positive vesicles). MPR300 co-locali-
zation analysis performed with anti-Rab7 antibody clearly identified an increase in MPR300 in
Rab7-positive vesicles from ASOTg/Tg neurons as the area of overlapping Rab7 and MPR300
increased (Fig 3C and 3D). In contrast MPR300 was reduced in the EEA1-positive vesicles
from ASOTg/Tg neurons (Fig 3A and 3D). Differently, we didn’t assess significant difference in
the extent of co-localization between MPR300 and TGN46 positive vesicles (Fig 3B and 3D).
We hypothesized that the reduction in MPR300 levels could be related to its altered traffick-
ing toward late endosomes and possibly also to lysosomes and we questioned whether lyso-
some inhibitors might rescue the MPR300 vesicles defect. To this aim we either inhibited
trafficking to lysosomes directly (chloroquine) or inactivated acidic hydrolases (NH4Cl) and
we noted that the number of MPR300 positive vesicles was significantly increased in response
to both chloroquine and NH4Cl inhibitors exposure in ASO cells (Fig 4B). Notably, the extent
of co-localization between MPR300 (green) and Lamp1 (red) immunofluorescence appeared to
be reduced in presence of chloroquine, likely suggesting a partial recovering of MPR300 traf-
ficking and sorting under lysosomal inhibitor exposure (Fig 4A and 4C).
The subcellular trafficking of MPR300 is complex and depends on interactions with cyto-
solic adaptors, such as AP-1, AP-2, GGA 1–3 and the retromer complex [49–51]. Newly syn-
thesized MPR300 can go directly to the plasma membrane where it is quickly internalized to
endosomes by an AP-2/clathrin-coated mechanism (the so-called indirect route). However, the
majority of MPR300 goes directly from the TGN to endosomes by AP-1 clathrin-coated vesi-
cles (the direct route). From endosomes, MPR300 is retrogradely transported to the TGN, a
mechanism that involves the retromer and the AP-1 multi-protein complex. Interestingly, a
lack of the AP-1μ subunit (AP1M1) has been previously reported to cause MPR300 mis-traf-
ficking in neurons with a consequent accumulation in the endosomes of μAP-1-/- cells [51, 52].
In order to evaluate whether AP-1 might play a role in the MPR300 and CD defects in our
experimental models, we assessed AP-1 expression levels from ASOTg/Tg mice and relative con-
trols. We noted a large decrease in AP-1 levels from ASOTg/Tg mice (Fig 5A), supporting the
hypothesis that a reduction in AP-1 prevents MPR300 returning back to the TGN, resulting in
its accumulation in endosomes and consequently in an increased exocytosis outside neurons.
It has been recently reported that depletion of VPS35 (an element of the retromer complex
involved in the transport of cargo from the endosome to the TGN) [53] might induce α-syn
accumulation in lysosomes by increasing the lysosomal turnover of MPR300 [54, 55]. We spec-
ulated on the possibility that α-syn overexpression may impair the expression levels of VPS35,
as observed for AP-1. We noted that VPS35 expression levels from ASO mice were not signifi-
cantly different when compared to the corresponding controls (Fig 5A). Moreover, the retro-
graded transported VPS10p-D receptors Sortilin and SorLA, which both shuttle between the
Table 1. qPCR onmRNA fromASOtg/tg and wildtype mice brain tissues. The tested genes encode CD
(ctds), MPR300 (Igf2r), SorLA (Sorl1), Sortilin (sort1), AP-1μ chain (Ap1m1) and AP-1γ chain (Ap1g1). For
each gene, all ASOtg/tg samples were normalised to the average of the 4 wildtype sample. The values in
parenthesis are the standard deviation on the fold change within each group.
Gene ID Aso (n = 6) Wt (n = 4) p-value
Ctds 1.01 (0.09) 1.00 (0.07) 0.87
Igf2r 1.03 (0.11) 1.00 (0.04) 0.82
Sorl1 0.95 (0.19) 1.00 (0.07) 0.58
Sort1 1.01 (0.24) 1.00 (0.16) 0.98
Ap1m1 0.96 (0.10) 1.00 (0.10) 0.56
Ap1g1 1.04 (0.14) 1.00 (0.10) 0.68
doi:10.1371/journal.pone.0160501.t001
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TGN and endosomal system like MPR300, were also not affected in ASOTg/Tg. Furthermore,
RT-PCR analysis clearly showed that the expression of all these proteins was not altered at the
mRNA level (Table 1).
To further test the hypothesis that α-syn overexpression might be related to defects in the
AP-1 route, we examined Lamp2 trafficking in Ctrl and ASO cells. Lamp-2 is normally directly
sorted from TGN to lysosomes via the endosomes [56], however in the absence of functional
AP-1 it would be expected that Lamp-2 is still directed to the lysosomes albeit mainly through
the indirect route via the plasma membrane. Technically this would result in an increased
Lamp-2 staining on the plasma membrane. In line with this hypothesis, we observed cell sur-
face staining for Lamp-2 in ASO cells but not in Ctrl, further indicating a general trafficking
failure in AP-1 sorted proteins (Fig 5B).
Fig 3. MPR300 preferentially localizes in late endosomes in ASOTg/Tg neurons. (A-C) Confocal microscopy analysis of MPR300 (green) and
EEA1, TGN46 and Rab7 (red), respectively, in WT and ASOTg/Tg cortical neurons. Scale bar 5 μm. (D) The extent of MPR300 co-localization to
EEA1, TGN46 and Rab7 is reported in panel D. Quantitative analysis was performed using Zen software. The (R) coefficient (Pearson’s
coefficient) was used for the quantitative and comparative analyses (R). Data are expressed as mean ± SEM. n = 8. *p<0.05. Two tailed T-Test).
doi:10.1371/journal.pone.0160501.g003
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The reduction in MPR300 intracellular levels of ASO cells and neurons is
due to increased degradation and secretion to the media
Under normal conditions, CD is efficiently sorted to the endocytic system with very little being
secreted from the cell [40]. However in some pathological conditions, proCD and CD can be
secreted into the extracellular space where these enzymes have been shown to contribute to the
invasive and metastatic properties of cancer cells [40, 57]. A similar fate has also been described
for MPR300 [58, 59]. To address the hypothesis that the reduction in MPR300 intracellular lev-
els also might be due to its secretion we first examined MPR300 levels in media from ASO cell
culture and neurons and in the correspondent controls. We found a significant increase in
MPR300 and α-syn secreted levels both in media from ASO cell and neurons (Fig 6A), sup-
porting the hypothesis that α-syn overexpression affects the endo-lysosomal pathway resulting
the mis-sorting and consequent secretion of MPR300. Notably, MPR300 levels were not differ-
ent between WT and ASO neurons (Fig 6A), suggesting that neuronal cultures might require
longer time in culture before showing significant evidence of reduced MPR300 expression lev-
els. Furthermore, the finding that secreted MPR300 levels are significantly increased in the
media from ASO neurons after 10 days in culture suggests that MPR300 secretion might pre-
cede its decrease that occurs later in neuronal cultures. Interestingly, proCD was undetectable
in media both of cell culture and neurons, suggesting that it is secreted in extremely low
amount in our experimental models (data not shown).
Additionally, we analysed protein levels of proCD and MPR300 both in the soluble (mostly
containing cytosolic proteins) and insoluble (mostly containing membranes) brain tissue frac-
tions of ASOTg/Tg mice and relevant controls. Notably, we found a large increase in soluble
Fig 4. The reduction in MPR300 levels is partially controlled by the exposure to lysosome inhibitors. (A) Confocal microscopy analysis of
MPR300 (green) and Lamp1 (red) positive vesicles. To counteract the decrease of MPR300 vesicles, Ctrl and ASO cells were exposed to vehicle,
Chloroquine (10mM) and NH4Cl (5mM) for 6 hrs. Images were also acquired on an automated Olympus microscope and the number of the
vesicles quantified using Scan^R imaging software (Olympus) (three slides per condition) (B). (N = 3; One-way Anova with post-hoc Tukey test)
*P<0.05 vs Ctrl. The extent of MPR300 co-localization to Lamp1 positive vesicles is reported in panel C. Quantitative analysis was performed
using Zen software. The (R) coefficient (Pearson’s coefficient) was used for the quantitative and comparative analyses (R). Data are expressed as
mean ± SEM. n = 4. *p<0.05 One-way Anova with post-hoc Tukey test).
doi:10.1371/journal.pone.0160501.g004
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MPR300 in ASOTg/Tg mouse brains that was consistent with its corresponding decrease in the
insoluble fractions (Fig 6B). ProCD was also higher in the soluble fraction of ASOTg/Tg mice
when compared to WT. However, due to the low expression levels of proCD in the correspon-
dent insoluble fraction, we detected no significant changes (Fig 6B).
In conclusion, we hypothesize that whereas MPR300 under normal conditions shuttles
between TGN and late endosomes, overexpression of α-syn results in a reduction of AP-1 that
consequently compromises the retrograde transport (Fig 7, route 2 and 4). A defect in MPR300
transport from endosomes to TGN will cause an accumulation of MPR300 in late endosomes.
This accumulation will eventually trigger MPR300 to follow the default pathways out of endo-
somes, which is to the lysosomes or to be secreted. Inefficient MPR300 trafficking will then be
followed by reduced proCD transport to lysosomes. Deficiency in retrograde MPR300 trans-
port can also be caused by a defect in the retromer complex as observed in the case with
Fig 5. AP1 protein levels are reduced in α-syn overexpressing mice cortex. (A) Western blot analysis of AP-1, AP-2, AP-3, SorLA, Sortilin and VPS35
fromWT and ASOTg/Tg cerebral cortical tissues. Optical density analysis is reported below. Data were normalized on the basis of the correspondent β–actin
values and expressed as % of WT. The experiments have been run 5 times in triplicate (N = 5; Two tailed-T test) (**) p<0.01 vs. WT. (B) Confocal
microscopy analysis of Lamp-2 surface staining on Ctrl and ASO cells with anti-Lamp2 antibody. Cells are stained with the primary antibody before
permeabilization.
doi:10.1371/journal.pone.0160501.g005
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familiar mutations in the VPS35 gene and by other cytosolic adaptor proteins [60, 61].
Although the VPS35 expression was not affected in our PD models, we cannot exclude that
other proteins involved in the retrograde MPR300 transport might be disturbed and conse-
quently influence MPR expression and trafficking in PD neurons.
MPR300 is reduced in human PD samples
Finally we investigated whether MPR300 expression was reduced in PD patients early during
the progression of the disease. To address this we performedWB for MPR300 and CD in SDS-
soluble lysates generated from PD patients selected with an early Braak Lewy body stage of 4 in
which α-syn deposition is largely confined to brainstem and basal forebrain regions. The same
Fig 6. MPR300 protein levels are significantly increased in the soluble fraction of ASOTg/Tg cortical tissues and in ASO cells. (A) Media
collected from ASO cells and the corresponding control (Ctrl) samples and from ASO andWT cortical neurons (after 10 days in culture)
were ultra-centrifuged at 100,000 rpm for 12 h. The pellets were solubilized in 2% SDS-loading buffer and (1/10 of the total amount)
analysed byWB for MPR300 and proCD. Total lysate was loaded and analysed on the samemembranes. proCDwas not detectable
under our experimental conditions (data not shown). TheWB is representative of 3 different experiments. Densitometric analysis of
MPR300 levels in media from ASO cells and neurons is reported below. Data were normalized on the basis of Hsc70 levels. The
experiments were run 3 times in triplicate (N = 3; Two-tailed-T test) (***) p<0.005 vs. WT. (B) WB analysis for MPR300 and proCD were
performed in the soluble and insoluble fractions from cortical tissues of ASOTg/Tg mice and the correspondent WT samples. Hsc70 (soluble and/or
secreted marker protein) [63, 64] (protocol is described in Methods) and Lamp1 blot were used as respective positive and negative controls of the
soluble and insoluble fractionations. The lack in Lamp1 blot signals in the media of cells and neuronal cultures indicates that there was no cell
leakage under our experimental conditions. Optical density analysis is reported below. Data were normalized on the basis of Hsc70 (soluble) or
Lamp1 (insoluble) levels and expressed as % of WT. The experiments were performed 4 times in triplicate (N = 4; Two tailed-T test) (*) p<0.05 and
(**) p<0.01 vs. WT.
doi:10.1371/journal.pone.0160501.g006
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Fig 7. Schematic drawing of MPR300 trafficking in cells. The top panel displays howMPR300 traffics in neurons under normal
physiological conditions. In short: after final glycosylation in the Golgi, MPR300 can either be secreted by a default route to the cell
membrane (1) or actively transported to the endo-lysosomal system by interacting with AP-1 and GGA 1–3 (2). MPR300 on the
membrane can be internalised via a coated pit to reach the endosomes (3). When MPR300 reaches endosomes, the retromer
complex and AP-1 facilitates the retrograde transport to the TGN (4). More than 90% of endogenously expressed MPR300 is
estimated to enter the TGN-endosome shuttle at any given time and this transport is essential for the transport of CD to lysosomes
(5). α-Syn enters the lysosomes via autophagosomes (6). The lower panel reports how a reduced MPR300 retrograde transport in
neurons likely influences proCD sorting in PD neurons (4). The reduction of MPR300 reduces the transport of proCD to the
endosomal system and its processing into the mature form of CD. Moreover, MPR300 accumulates in the membrane of late
endosomes and in the intraluminal vesicles (ILV). Finally, the only escape from endosomes is by lysosomal degradation or secretion
(in this latter case the ILV are termed exosomes).
doi:10.1371/journal.pone.0160501.g007
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cases have previously been used to measure CD levels with the finding that the protein was
increased in PD [22]. While this case selection process limited the number of PD cases for evalua-
tion, this cohort provided an opportunity to better understand earlier pathogenic events com-
pared to late end-stage PD cases. In these cases and matched controls, tissue from the anterior
cingulate cortex were evaluated where we have previously shown early biochemical changes in the
presence of increased SDS-soluble α-syn, but not yet Lewy body pathology [22]. WB data were
normalised to β-actin and multivariate analysis (covarying for age and post-mortem delay) used
to determine changes in α-syn and MPR300 in the PD group compared to control. The analysis
revealed a significant decrease in MPR300 protein in the PD group (Fig 8) and as expected α-syn
Fig 8. MPR300 is decreased in human brain from patients with early PD.WB of MPR300 and α-syn in SDS-soluble protein lysates
generated from the anterior cingulate cortex of 6 autopsy-confirmed patients with Braak Lewy body stage 4 (PD) [65] versus 9 controls as
detailed in the table below reporting their demographic details. Immunoblot data was normalized to β-actin and a multivariate analysis
performed to determine if MPR300 or α-syn were changed in PD. Age and post-mortem delay were included as covariates. The results show
a significant reduction in MPR300 protein and an expected significant increase in α-syn levels in PD anterior cingulate cortex. Values are
given as mean ± SEM and * = p<0.05.
doi:10.1371/journal.pone.0160501.g008
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was significantly increased (Fig 8). Age (p = 0.21) and post mortem delay (p = 0.10) had no signif-
icant influence on the protein levels of MPR300 or α-syn.
Interestingly, CD appeared to be almost completely processed to generate the active mature
form (CD 32Da) in the postmortem tissues from PD patients. Based on the present results and
the results from data in a primate PD model [62], we predict that any increase in CD would be
mis-localised at this early disease stage. Thus, defects in MPR300 may precede the mis-localisa-
tion of CD resulting in the increase of insoluble α-syn and ultimately a decrease in mature CD
in appropriate functional compartments as Lewy pathology develops. These results are sup-
ported by other tissue studies in the very vulnerable PD substantia nigra showing reduced CD
in association with Lewy pathology [5]. Our results are consistent with such pathology occur-
ring following defective MPR300 transport.
Conclusions
We present here a new scenario for PD in which α-syn overexpression induces defects in AP-1
mediated MPR300 trafficking and sorting using, cell lines, mouse models and clinical samples.
Accordingly, a decrease in MPR300 levels, and its altered shuttling between endosomes and the
TGN, causes an improper cathepsin D (CD) trafficking to lysosomes and likely α-syn accumu-
lation in neurons, finally related to PD disease. These results pinpoint MPR300 as a potential
biomarker for PD prediction.
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